AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer

被引：6

作者：

Spirina, L. V. ^{[1
,2
]}

Avgustinovich, A. V. ^{[1
]}

Afanas'ev, S. G. ^{[1
]}

Kondakova, I. V. ^{[1
]}

Volkov, M. Yu. ^{[1
]}

Dobrodeev, A. Yu. ^{[1
]}

Boronkina, A. I. ^{[2
]}

机构：

[1] Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia

[2] Siberian State Med Univ, Minist Hlth Russian Federat, Tomsk, Russia

来源：

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2020年 / 170卷 / 01期

关键词：

gastric cancer; AKT; mTOR signaling cascade; PD; PD-L1; PD-L2; PATHWAY; AKT;

D O I：

10.1007/s10517-020-05007-0

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The peculiarities of gastric cancer development associated with the expression levels of components of the AKT/mTOR signaling cascade and PD, PD-L1, PD-L2 have not yet been identified. We revealed the fundamental changes in the expression AKT/mTOR and PD receptors and their ligands associated with dissemination of gastric cancer. An increase in the mRNA level of all components of this cascade was demonstrated. The expression of mTOR and AKT decreased against the background of enhanced expression of PTEN phosphatase. The increase in the expression of PD-1 receptors and PD-L1 and PD-L2 ligands was most pronounced in patients with distant metastases.

引用

页码：75 / 78

页数：4

共 50 条

[31] PD-1 AND PD-L1 EXPRESSION IN OVARIAN CANCER
Wieser, V.
Gaugg, I.
Fleischer, M.
Fiegl, H.
Marth, C.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 64 - 64
[32] PD-1 and PD-L1 expression in ovarian cancer
Wieser, V.
Gaugg, I.
Fleischer, M.
Reimer, D.
Zeimet, A.
Fiegl, H.
Marth, C.
ANNALS OF ONCOLOGY, 2016, 27
[33] Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues
Ishida, M
Iwai, Y
Tanaka, Y
Okazaki, T
Freeman, GJ
Minato, N
Honjo, T
IMMUNOLOGY LETTERS, 2002, 84 (01) : 57 - 62
[34] PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment (vol 121, pg 251, 2015)
Mathios, Dimitrios
Ruzevick, Jacob
Jackson, Christopher M.
Xu, Haiying
Shah, Sagar R.
Taube, Janis M.
Burger, Peter C.
McCarthy, Edward F.
Quinones-Hinojosa, Alfredo
Pardoll, Drew M.
Lim, Michael
JOURNAL OF NEURO-ONCOLOGY, 2016, 128 (01) : 183 - 183
[35] Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation
Kinch, Amelie
Sundstrom, Christer
Baecklund, Eva
Backlin, Carin
Molin, Daniel
Enblad, Gunilla
LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 376 - 384
[36] Association of PD-1, PD-L1 and PD-L2 expression with clinicopathological factors in tongue squamous cell carcinoma
Tsuchihashi, Kei
Nakatsugawa, Munehide
Asanuma, Hiroko
Miyazaki, Akihiro
Torigoe, Toshihiko
CANCER SCIENCE, 2018, 109 : 498 - 498
[37] Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
Kwiecien, Iwona
Rutkowska, Elzbieta
Polubiec-Kownacka, Malgorzata
Raniszewska, Agata
Rzepecki, Piotr
Domagala-Kulawik, Joanna
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (04) : 1679 - 1689
[38] Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
Javan, Mohammad Reza
Aslani, Saeed
Zamani, Mohammad Reza
Rostamnejad, Javad
Asadi, Milad
Farhoodi, Mahdi
Nicknam, Mohammad Hossein
IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2016, 15 (04) : 296 - 302
[39] Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
Jeong, Seri
Lee, Nuri
Park, Min-Jeong
Jeon, Kibum
Song, Wonkeun
CANCERS, 2021, 13 (20)
[40] PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
Rotman, Jossie
Otter, Leontine A. S. den
Bleeker, Maaike C. G.
Samuels, Sanne S.
Heeren, A. Marijne
Roemer, Margaretha G. M.
Kenter, Gemma G.
Zijlmans, Henry J. M. A. A.
van Trommel, Nienke E.
de Gruijl, Tanja D.
Jordanova, Ekaterina S.
FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →